All articles tagged with #novo nordisk
Originally Published 2 days ago — by CNBC
Amazon Pharmacy now offers Novo Nordisk's Wegovy weight loss pill, including an oral version with competitive pricing, expanding access to obesity treatments beyond traditional channels and reaching new patients through online and physical pharmacy outlets.
Originally Published 2 days ago — by Reuters
Amazon Pharmacy now offers Novo Nordisk's Wegovy weight-loss pill through insurance and cash options, with prices starting at $25 for insured and $149 for cash-paying customers, expanding access via kiosks and collaborations with telehealth providers, as the drug gains FDA approval and aims to attract new consumers seeking an alternative to injectable treatments.
Originally Published 6 days ago — by The Guardian
Novo Nordisk has launched Wegovy, a lower-cost, pill-form weight-loss drug in the US, sparking a price war in the sector and offering a needle-free alternative to injectable GLP-1 medications, with significant implications for obesity treatment affordability and accessibility.
Originally Published 6 days ago — by CBS News
Novo Nordisk has launched an oral version of its weight-loss drug Wegovy in the U.S., offering a convenient alternative to injections. The pill, containing semaglutide, was approved by the FDA in December and is available for $149 per month for initial doses, with prices increasing later in April. Clinical trials show significant weight loss benefits, making it a notable innovation in obesity treatment.
Originally Published 6 days ago — by Financial Times
Novo Nordisk has announced a price reduction for its Wegovy weight-loss pill in the US to compete with Eli Lilly's market offerings, initiating a price war in the weight-loss drug industry. The company will offer lower doses at significantly reduced prices, aiming to attract more overweight and obese patients, especially following the recent FDA approval of an oral version of Wegovy. This move comes amid a competitive landscape with Lilly's upcoming drug, orforglipron, expected to be approved soon.
Originally Published 6 days ago — by CNN
Americans can now access a daily pill form of Wegovy, a popular weight-loss drug, which is generally cheaper than the weekly injection and is available with a prescription. The pill contains the same active ingredient as the injection, semaglutide, and offers an alternative for those seeking weight management solutions, with pricing options and insurance savings programs. The FDA approved the oral version in late December, and it shows similar efficacy and side effects to the injectable form.
Originally Published 6 days ago — by CNBC
Novo Nordisk launches the first oral GLP-1 pill for weight loss in the U.S., offering a more affordable and accessible alternative to injections, with prices ranging from $149 to $299 per month, and aims to capture a significant share of the growing obesity treatment market.
Originally Published 6 days ago — by PR Newswire
Novo Nordisk's Wegovy® pill, the first oral GLP-1 medication for weight loss, is now widely available across US pharmacies and telehealth providers, offering an effective option for adults with obesity or overweight with medical issues, with an average weight loss of about 17% if all patients stay on treatment.
Originally Published 14 days ago — by Yahoo Finance
Novo Nordisk received FDA approval for Wegovy, the first oral GLP-1 medication for weight loss, which could significantly impact the obesity treatment industry by offering a more convenient option and potentially increasing market share amid rising competition and pricing pressures.
Originally Published 15 days ago — by The Motley Fool
The article discusses the recent developments in the GLP-1 drug market, highlighting Novo Nordisk's new pill and the potential of out-of-favor drug makers like Bristol Myers Squibb, Merck, and Pfizer as long-term investment opportunities due to their efforts to innovate and survive patent cliffs. Despite current setbacks, these companies are positioned for future growth, making them attractive for contrarian investors.
Originally Published 16 days ago — by The Motley Fool
Novo Nordisk's stock, after a significant decline in 2025 due to competition and market pressures, could rebound strongly in 2026 with the FDA approval of its oral Wegovy pill, a major development in obesity treatment. The new pill is expected to boost the company's growth prospects, potentially leading to a substantial stock price increase and making it an attractive investment opportunity, especially if the company maintains or exceeds its current growth rate.
Originally Published 17 days ago — by Yahoo Finance
Novo Nordisk's stock faced challenges in 2025 due to competition and demand issues, but the FDA approval of its Wegovy pill and plans to launch an oral version in 2026 present a strategic comeback opportunity, prompting investors to consider whether to buy, sell, or hold the stock.
Originally Published 19 days ago — by CNBC
European markets closed mixed with Novo Nordisk shares jumping 9.2% after FDA approval for a GLP-1 pill, while Sanofi announced a $2.2 billion acquisition. Gold and silver futures hit new highs, and U.S. visa bans were imposed on EU officials involved in social media censorship. Asia-Pacific markets traded mostly higher, and U.S. futures remained flat despite record closes for the S&P 500.
Originally Published 19 days ago — by CNBC
The article highlights the biggest midday stock movements involving companies like Novo Nordisk, ServiceNow, Freeport-McMoRan, and Structure Therapeutics, indicating notable activity in the stock market.
Originally Published 19 days ago — by TipRanks
Eli Lilly's stock declined after its rival Novo Nordisk received U.S. approval for its obesity medication, impacting investor sentiment in the pharmaceutical sector.